|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that it will be presenting at BioContact Quebec 2007 in Quebec City.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, has closed its previously announced private placement with aggregate gross proceeds to the Company of $428,000 from the sale of 1,222,858 units at a price of $0.35 per Unit.
Read More
|
|
WINNIPEG, Manitoba (August 17, 2007) - Miraculins Inc. (TSX-V: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, today announces an amendment to the previously announced non-brokered private placement offering.
Read More
|
|
Miraculins Inc. (TSX-V: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, today announces a non-brokered private placement offering.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce further results that indicate its prostate cancer test could be used as a tumor grading test.
Read More
|
|
|